https://scholars.lib.ntu.edu.tw/handle/123456789/596495
標題: | Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience | 作者: | Tan B. JYH-CHIN YANG Young C.L. Bishu S. Owyang S.Y. El-Zaatari M. Zhang M. Grasberger H. Qian J.-M. Kao J.Y. |
關鍵字: | Antibiotic resistance; Culture; Helicobacter pylori; Salvage therapy | 公開日期: | 2018 | 出版社: | Springer New York LLC | 卷: | 63 | 期: | 2 | 起(迄)頁: | 437-445 | 來源出版物: | Digestive Diseases and Sciences | 摘要: | Background: The current practice guidelines recommend that Helicobacter pylori (H. pylori) culture and antimicrobial susceptibility testing (AST) be considered after patients failed the second course of H. pylori eradication therapy. Aims: Here we report the real life experience of following this recommendation in the USA. Methods: We established an in-house H. pylori culture protocol for AST and identified retrospectively patients who previously failed ??2 courses of anti-H. pylori therapy and underwent esophagogastroduodenoscopy with AST at University of Michigan from 2010 to 2017. We determined the rate of H. pylori antibiotic resistance, the success rates of AST-guided tailored therapy, and the risk factors associated with treatment failure. Results: Forty-seven patients were identified and 34 (72.3%) had successful cultures and AST. The most common antibiotic resistance was to metronidazole (79.4%), followed by clarithromycin (70.6%) and ciprofloxacin (42.9%). None of the patients were resistant to amoxicillin or tetracycline. The overall success rate of AST-guided tailored therapy was low (44.4%, 12/27). In patients infected with metronidazole-resistant H. pylori, bismuth quadruple therapy appears to be superior compared to non-bismuth quadruple therapy (6/8 or 75.0% vs. 3/14 or 21.4%, P?=?0.03). High body mass index was significantly associated with tailored therapy failure (OR 1.24, 95% CI 1.00–1.54, P?=?0.049). Conclusions: The success rate of AST-guided salvage therapy in the USA is low particularly in those with high BMI. Bismuth-based therapy appears to be better than non-bismuth-based regimens. ? 2017, Springer Science+Business Media, LLC, part of Springer Nature. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038617859&doi=10.1007%2fs10620-017-4880-8&partnerID=40&md5=745e3f7f9d5ca1a5bb12844761ce426d https://scholars.lib.ntu.edu.tw/handle/123456789/596495 |
ISSN: | 0163-2116 | DOI: | 10.1007/s10620-017-4880-8 | SDG/關鍵字: | amoxicillin; antibiotic agent; bismuth derivative; ciprofloxacin; clarithromycin; levofloxacin; metronidazole; proton pump inhibitor; rifabutin; tetracycline; antiinfective agent; bismuth; proton pump inhibitor; adult; antibiotic resistance; antibiotic sensitivity; antibiotic therapy; Article; bacterium culture; body mass; clinical article; combination drug therapy; drug megadose; drug treatment failure; eradication therapy; esophagogastroduodenoscopy; female; follow up; Helicobacter infection; Helicobacter pylori; human; human tissue; infection risk; male; middle aged; nonhuman; obesity; personal experience; polypharmacy; priority journal; retrospective study; salvage therapy; stomach biopsy; tetracycline resistance; United States; antibiotic resistance; drug effect; Helicobacter infection; Helicobacter pylori; microbiology; salvage therapy; treatment failure; Adult; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure; United States |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。